Why We Need an Efficient and Careful Pharmacovigilance

[1]  C. Pamer,et al.  Postmarketing surveillance of suicidal adverse events with pediatric use of antidepressants. , 2006, Journal of child and adolescent psychopharmacology.

[2]  S. Evans,et al.  Use of proportional reporting ratios (PRRs) for signal generation from spontaneous adverse drug reaction reports , 2001, Pharmacoepidemiology and drug safety.

[3]  B. Hoogwerf,et al.  Efficacy of GLP-1 receptor agonists and DPP-4 inhibitors: meta-analysis and systematic review. , 2012, Clinical therapeutics.

[4]  R. Elble,et al.  Lung Endothelial Dipeptidyl Peptidase IV Promotes Adhesion and Metastasis of Rat Breast Cancer Cells via Tumor Cell Surface-associated Fibronectin* , 1998, The Journal of Biological Chemistry.

[5]  Stephanie J. Reisinger,et al.  Drug-versus-Drug Adverse Event Rate Comparisons , 2009, Drug safety.

[6]  M. Lindquist,et al.  A comparison of measures of disproportionality for signal detection in spontaneous reporting systems for adverse drug reactions , 2002, Pharmacoepidemiology and drug safety.

[7]  D. Harlan,et al.  Diabetes and Cancer , 2010, Diabetes Care.

[8]  Iraklis Varlamis,et al.  Use of social media by healthcare professionals in Greece: an exploratory study , 2012, Int. J. Electron. Heal..

[9]  Yasushi Okuno,et al.  Adverse Event Profiles of Platinum Agents: Data Mining of the Public Version of the FDA Adverse Event Reporting System, AERS, and Reproducibility of Clinical Observations , 2011, International journal of medical sciences.

[10]  N. Hawkes.  Journal withdraws article after complaints from drug manufacturers , 2011, BMJ : British Medical Journal.

[11]  Lower Risk of Cancer in Patients on Metformin in Comparison With Those on Sulfonylurea Derivatives , 2011, Diabetes Care.

[12]  Bryant Thomas Karras,et al.  Design and Implementation of Cell-PREVEN: A Real-Time Surveillance System for Adverse Events Using Cell Phones in Peru , 2005, AMIA.

[13]  R. Elashoff,et al.  Pancreatitis, pancreatic, and thyroid cancer with glucagon-like peptide-1-based therapies. , 2011, Gastroenterology.

[14]  Elisabetta Poluzzi,et al.  Assessing the Association of Pioglitazone Use and Bladder Cancer Through Drug Adverse Event Reporting , 2011, Diabetes Care.

[15]  Beatrice A. Golomb,et al.  A Survey of the FDA's AERS Database Regarding Muscle and Tendon Adverse Events Linked to the Statin Drug Class , 2012, PloS one.

[16]  P. Stolley,et al.  Nonhormonal drugs and cancer. , 1995, Environmental health perspectives.

[17]  H. Yabuuchi,et al.  Platinum Agent-Induced Hypersensitivity Reactions: Data Mining of the Public Version of the FDA Adverse Event Reporting System, AERS , 2011, International journal of medical sciences.

[18]  S. Zucker,et al.  The protease complex consisting of dipeptidyl peptidase IV and seprase plays a role in the migration and invasion of human endothelial cells in collagenous matrices. , 2006, Cancer research.

[19]  R. Meyboom,et al.  Use of Dipeptidyl Peptidase-4 Inhibitors and the Reporting of Infections: A Disproportionality Analysis in the World Health Organization VigiBase , 2011, Diabetes Care.

[20]  Aune Moro,et al.  Metformin Inhibits the Growth of Human Pancreatic Cancer Xenografts , 2013, Pancreas.

[21]  W. Chou,et al.  Social Media Use in the United States: Implications for Health Communication , 2009, Journal of medical Internet research.

[22]  Yasushi Okuno,et al.  Hypersensitivity reactions to anticancer agents: Data mining of the public version of the FDA adverse event reporting system, AERS , 2011, Journal of experimental & clinical cancer research : CR.

[23]  W. DuMouchel,et al.  Novel Statistical Tools for Monitoring the Safety of Marketed Drugs , 2007, Clinical pharmacology and therapeutics.

[24]  A. Bate,et al.  A Bayesian neural network method for adverse drug reaction signal generation , 1998, European Journal of Clinical Pharmacology.

[25]  Stephen Mifsud,et al.  Strengthening and Rationalizing Pharmacovigilance in the EU: Where is Europe Heading to? , 2011, Drug safety.

[26]  J. Manson,et al.  Estrogen plus progestin and breast cancer incidence and mortality in postmenopausal women. , 2010, JAMA.

[27]  H. Kennedy,et al.  Pancreatic cancer: a review of the evidence on causation. , 2008, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[28]  Xilin Yang,et al.  Associations of Hyperglycemia and Insulin Usage With the Risk of Cancer in Type 2 Diabetes: The Hong Kong Diabetes Registry , 2010, Diabetes.

[29]  E. Vandewater,et al.  Media, social networking, and pediatric obesity. , 2011, Pediatric clinics of North America.

[30]  A Lawrence Gould,et al.  Practical pharmacovigilance analysis strategies. , 2003, Pharmacoepidemiology and drug safety.

[31]  A. Bate,et al.  Quantitative signal detection using spontaneous ADR reporting , 2009, Pharmacoepidemiology and drug safety.

[32]  R. Hoover,et al.  Drug‐induced cancer , 1981, Journal of the National Cancer Institute.

[33]  M. Pendergrass,et al.  Acute Pancreatitis in Type 2 Diabetes Treated With Exenatide or Sitagliptin , 2010, Diabetes Care.

[34]  R. O’Neill,et al.  Use of Screening Algorithms and Computer Systems to Efficiently Signal Higher-Than-Expected Combinations of Drugs and Events in the US FDA’s Spontaneous Reports Database , 2002, Drug safety.